## Brian J Angus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8903747/publications.pdf

Version: 2024-02-01

41258 15683 19,443 133 49 125 citations h-index g-index papers 166 166 166 26768 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase $1/2$ , single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
3	Mortality after Fluid Bolus in African Children with Severe Infection. New England Journal of Medicine, 2011, 364, 2483-2495.	13.9	1,871
4	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
5	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of $ChAdOx1 nCoV-19 (AZD1222) vaccine$ : a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
6	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	15.2	900
7	Oral versus Intravenous Antibiotics for Bone and Joint Infection. New England Journal of Medicine, 2019, 380, 425-436.	13.9	548
8	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
9	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	15.2	473
10	Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine, 2021, 31, 100683.	3.2	435
11	Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines. JAMA - Journal of the American Medical Association, 2016, 315, 1610.	3.8	266
12	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	15.2	265
13	Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet, The, 2017, 390, 2472-2480.	6.3	251
14	Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells. Journal of Infectious Diseases, 2012, 205, 1408-1416.	1.9	235
15	Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials. Clinical Infectious Diseases, 2012, 55, S93-S103.	2.9	228
16	Artemisinin combination therapy for vivax malaria. Lancet Infectious Diseases, The, 2010, 10, 405-416.	4.6	204
17	Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood, 2005, 106, 2444-2451.	0.6	184
18	Comparison of Imipenem and Ceftazidime as Therapy for Severe Melioidosis. Clinical Infectious Diseases, 1999, 29, 381-387.	2.9	167

#	Article	IF	CITATIONS
19	Comprehensive Cardiac Magnetic Resonance Imaging and Spectroscopy Reveal a High Burden of Myocardial Disease in HIV Patients. Circulation, 2013, 128, 814-822.	1.6	160
20	Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. Aids, 2010, 24, 697-706.	1.0	150
21	Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2012, 308, 353-61.	3.8	146
22	Sequence Analysis of <i>In Vivo</i> Defective Interfering-Like RNA of Influenza A H1N1 Pandemic Virus. Journal of Virology, 2013, 87, 8064-8074.	1.5	144
23	NCL-CD10–270: A New Monoclonal Antibody Recognizing CD10 in Paraffin-Embedded Tissue. American Journal of Pathology, 1999, 154, 77-82.	1.9	137
24	Prognostic Significance of Reduced Red Blood Cell Deformability in Severe Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 1997, 57, 507-511.	0.6	131
25	Hodgkin's disease in the elderly: a population-based study. British Journal of Haematology, 2002, 119, 432-440.	1.2	130
26	An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate Solution. Clinical Infectious Diseases, 2014, 58, 1230-1240.	2.9	126
27	Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malaria Journal, 2011, 10, 352.	0.8	111
28	Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Science Translational Medicine, 2015, 7, 300ra126.	5.8	109
29	NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. Journal of Pathology, 1990, 161, 15-25.	2.1	108
30	In Vivo Removal of Malaria Parasites From Red Blood Cells Without Their Destruction in Acute Falciparum Malaria. Blood, 1997, 90, 2037-2040.	0.6	108
31	British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIVâ€seropositive individuals 2011. HIV Medicine, 2011, 12, 1-5.	1.0	99
32	A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults. Clinical Infectious Diseases, 2011, 52, 736-742.	2.9	97
33	Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosomes and Cancer, 1995, 12, 152-156.	1.5	93
34	A Comparison of Chloramphenicol, Trimethoprimâ€Sulfamethoxazole, and Doxycycline with Doxycycline Alone as Maintenance Therapy for Melioidosis. Clinical Infectious Diseases, 1999, 29, 375-380.	2.9	88
35	Randomized Comparison of Artesunate and Quinine in the Treatment of Severe Falciparum Malaria. Clinical Infectious Diseases, 2003, 37, 7-16.	2.9	81
36	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T <sub>H</sub> 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	5.8	80

#	Article	IF	CITATIONS
37	British HIV Association guidelines for the treatment of $\langle scp \rangle HIV \langle scp \rangle \hat{a} \in 1 \hat{a} \in positive$ adults with antiretroviral therapy 2015. HIV Medicine, 2016, 17, s2-s104.	1.0	78
38	Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11. Journal of Pathology, 1991, 163, 105-110.	2.1	75
39	Antiviral Inhibitory Capacity of CD8+ÂT cells Predicts the Rate of CD4+ÂT-Cell Decline in HIV-1 Infection. Journal of Infectious Diseases, 2012, 206, 552-561.	1.9	74
40	Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study. Journal of Pathology, 1992, 168, 23-28.	2.1	72
41	Oral Artesunate Dose-Response Relationship in Acute Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2002, 46, 778-782.	1.4	68
42	Prime and target immunization protects against liver-stage malaria in mice. Science Translational Medicine, $2018,10,.$	5.8	68
43	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Neglected Tropical Diseases, 2016, 10, e0004926.	1.3	67
44	Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans. Journal of Translational Medicine, 2016, 14, 62.	1.8	67
45	Clinical Research in Resource-Limited Settings: Enhancing Research Capacity and Working Together to Make Trials Less Complicated. PLoS Neglected Tropical Diseases, 2010, 4, e619.	1.3	62
46	Glucose and Lactate Kinetics in Children with Severe Malaria < sup>1 < /sup>. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1569-1576.	1.8	61
47	Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. Clinical Infectious Diseases, 2017, 64, 1066-1073.	2.9	60
48	New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. , $1997, 183, 228-232$ .		59
49	Cutaneous Tuberculosis of the Penis and Sexual Transmission of Tuberculosis Confirmed by Molecular Typing. Clinical Infectious Diseases, 2001, 33, e132-e134.	2.9	57
50	The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. PLoS ONE, 2013, 8, e57121.	1.1	54
51	Strategies for developing sustainable health research capacity in low and middle-income countries: a prospective, qualitative study investigating the barriers and enablers to locally led clinical trial conduct in Ethiopia, Cameroon and Sri Lanka. BMJ Open, 2017, 7, e017246.	0.8	52
52	An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): Evidence for a specific association with EBV+ve HD in young adults. International Journal of Cancer, 2003, 107, 298-302.	2.3	51
53	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. Npj Vaccines, 2018, 3, 49.	2.9	51
54	Activation of Salmonella Typhi-Specific Regulatory T Cells in Typhoid Disease in a Wild-Type S. Typhi Challenge Model. PLoS Pathogens, 2015, 11, e1004914.	2.1	50

#	Article	lF	CITATIONS
55	A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor) Tj ETQq1 1693-696.	. 0.784314 rgBT 1.4	/Overlock 1 49
56	Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. Trials, 2015, 16, 583.	0.7	48
57	Interruption of antiretroviral therapy is associated with increased plasma cystatin C. Aids, 2009, 23, 71-82.	1.0	47
58	Challenge of Humans with Wild-type Salmonella enterica Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. Frontiers in Immunology, 2017, 8, 398.	2.2	47
59	Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. Journal of Experimental Medicine, 2016, 213, 1061-1077.	4.2	45
60	Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per $\hat{1}^1/4$ L: secondary outcome results from a randomised controlled trial. Lancet HIV,the, 2017, 4, e105-e112.	2.1	44
61	Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. Journal of Infection, 2019, 78, 382-392.	1.7	42
62	Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. Journal of Psychosomatic Research, 2014, 77, 20-26.	1.2	41
63	Advancing the management and control of typhoid fever: A review of the historical role of human challenge studies. Journal of Infection, 2014, 68, 405-418.	1.7	40
64	Short Report: Rosette Formation in Plasmodium ovale Infection. American Journal of Tropical Medicine and Hygiene, 1996, 55, 560-561.	0.6	40
65	Cytokeratins in cervical dysplasia and neoplasia: A comparative study of immunohistochemical staining using monoclonai antibodies NCL-5D3, CAM 5·2, and PKK1. Journal of Pathology, 1988, 155, 71-7	5. <sup>2.1</sup>	39
66	Relationships between oestrogen receptor, epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer. Journal of Pathology, 1988, 155, 143-150.	2.1	38
67	Evaluation of the immunogenicity and impact on the latent HIVâ€1 reservoir of a conserved region vaccine, MVA.HIVconsy, in antiretroviral therapyâ€treated subjects. Journal of the International AIDS Society, 2017, 20, 21171.	1.2	36
68	Plasma nitrogen oxides and blood lactate concentrations in Ghanaian children with malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 298-302.	0.7	34
69	Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leukemia and Lymphoma, 2006, 47, 223-230.	0.6	34
70	THE PATHOLOGICAL AND BIOLOGICAL NATURE OF SCREEN-DETECTED BREAST CARCINOMAS: A MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY. , 1997, 182, 29-35.		33
71	A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. British Journal of Clinical Pharmacology, 2001, 52, 655-661.	1.1	33
72	Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model. Nature Medicine, 2019, 25, 1082-1088.	15.2	33

#	Article	IF	CITATIONS
73	Comparative Assessment Expression of the Inhibitor of Growth 1 Gene (ING1) in Normal and Neoplastic Tissues. Hybridoma, 2002, 21, 1-10.	0.6	30
74	Importance of Salmonella Typhi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model. Frontiers in Immunology, 2017, 8, 208.	2.2	30
<b>7</b> 5	Understanding the investigators: a qualitative study investigating the barriers and enablers to the implementation of local investigator-initiated clinical trials in Ethiopia. BMJ Open, 2013, 3, e003616.	0.8	29
76	Omenn's syndrome occurring in patients without mutations in recombination activating genes. Clinical Immunology, 2005, $116$ , $246$ - $256$ .	1.4	28
77	Prognostic indicators in adults hospitalized with falciparum malaria in Western Thailand. Malaria Journal, 2013, 12, 229.	0.8	27
78	Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. Journal of Immunological Methods, 2013, 391, 174-178.	0.6	26
79	Novel anti-malarial combinations and their toxicity. Expert Review of Clinical Pharmacology, 2014, 7, 299-316.	1.3	26
80	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. Clinical Infectious Diseases, 2019, 68, 1265-1273.	2.9	26
81	Prognostic significance of immunohistochemistryâ€based markers and algorithms in immunochemotherapyâ€treated diffuse large <scp>B</scp> cell lymphoma patients. Histopathology, 2013, 63, 788-801.	1.6	25
82	RETINOBLASTOMA PROTEIN IN HUMAN BREAST CARCINOMA: IMMUNOHISTOCHEMICAL STUDY USING A NEW MONOCLONAL ANTIBODY EFFECTIVE ON ROUTINELY PROCESSED TISSUES. , 1996, 180, 65-70.		24
83	A family with adult-onset cerebral adrenoleucodystrophy. Journal of Neurology, 1994, 241, 497-499.	1.8	23
84	The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study. PLoS ONE, 2014, 9, e92606.	1.1	23
85	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. International Journal of Oncology, 2010, 37, 367-76.	1.4	22
86	Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. PLoS Neglected Tropical Diseases, 2019, 13, e0007955.	1.3	21
87	Oral Challenge with Wild-Type Salmonella Typhi Induces Distinct Changes in B Cell Subsets in Individuals Who Develop Typhoid Disease. PLoS Neglected Tropical Diseases, 2016, 10, e0004766.	1.3	20
88	Oral Wild-Type Salmonella Typhi Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who Develop Typhoid Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0003837.	1.3	18
89	Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study. PLoS ONE, 2013, 8, e56249.	1.1	18
90	Polymorphous lymphoproliferative disorder with Hodgkin-like features in common γ-chain–deficient severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2011, 127, 533-535.	1.5	16

#	Article	IF	CITATIONS
91	Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. PLoS ONE, 2011, 6, e14764.	1.1	16
92	Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers. BMJ Open, 2015, 5, e007481-e007481.	0.8	16
93	Response to the editorial by Dr Geraghty. Journal of Health Psychology, 2017, 22, 1113-1117.	1.3	16
94	Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015. Open Forum Infectious Diseases, 2017, 4, ofx212.	0.4	16
95	Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 160-166.	0.9	16
96	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. International Journal of Oncology, 2009, 35, 961-71.	1.4	15
97	Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization. Contemporary Clinical Trials Communications, 2019, 15, 100401.	0.5	15
98	Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model. PLoS Neglected Tropical Diseases, 2020, 14, e0008783.	1.3	15
99	Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: The INSIGHT FLU 002 and FLU 003 studies. Vaccine, 2011, 29, B56-B62.	1.7	14
100	Expression of growth regulatory genes in a SCID mouse-human model of intestinal epithelial regeneration., 1999, 187, 229-236.		13
101	Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 184-186.	0.7	13
102	Barriers and enablers of locally led clinical trials in Ethiopia and Cameroon: a prospective, qualitative study. Lancet, The, 2013, 382, 14.	6.3	12
103	Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein. , 1997, 72, 614-618.		11
104	Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 382-391.	0.9	11
105	Alpha interferon gene deletions in post-transplant lymphoma. British Journal of Haematology, 1997, 98, 1002-1003.	1.2	10
106	The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer. Cancer Immunology, Immunotherapy, 1995, 41, 137-145.	2.0	8
107	Cyclin D3 Expression, Cell Proliferation and Pathological Stage of Human Primary Colorectal Cancer. Oncology, 1999, 56, 66-72.	0.9	8
108	Protein and energy metabolism in chronic bacterial infection: studies in melioidosis. Clinical Science, 2001, 100, 101-110.	1.8	8

#	Article	IF	Citations
109	Protein and energy metabolism in chronic bacterial infection: studies in melioidosis. Clinical Science, 2001, 100, 101.	1.8	8
110	Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV Medicine, 2011, 12, 219-227.	1.0	8
111	Oestrogen receptor and oestrogen regulated proteins in human breast cancer: A review Keio Journal of Medicine, 1989, 38, 241-261.	0.5	8
112	Response of PUVA-induced keratoses to etretinate. Journal of the American Academy of Dermatology, 1996, 35, 120-123.	0.6	7
113	Malaria on the World Wide Web. Clinical Infectious Diseases, 2001, 33, 651-661.	2.9	7
114	TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. Aids, 2008, 22, 737-740.	1.0	6
115	Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. Clinical Infectious Diseases, 2018, 67, 341-349.	2.9	6
116	A flow cytometric study of c-erbB-3 expression in breast cancer. Cancer Immunology, Immunotherapy, 1995, 41, 280-286.	2.0	5
117	Neurochemical abnormalities in chronic fatigue syndrome: a pilot magnetic resonance spectroscopy study at 7 Tesla. Psychopharmacology, 2022, 239, 163-171.	1.5	5
118	Mucosal-Associated Invariant T cells exhibit distinct functional signatures associated with protection against typhoid fever. Cellular Immunology, 2022, 378, 104572.	1.4	5
119	Emergence of a distinct <scp>HIV</scp> â€specific <scp>IL</scp> â€10â€producing <scp>CD</scp> 8 <sup>+</sup> <scp>T</scp> â€cell subset with immunomodulatory functions during chronic <scp>HIV</scp> â€1 infection. European Journal of Immunology, 2013, 43, 2875-2885.	1.6	4
120	Investigating Systemic Immunity to Typhoid and Paratyphoid Fever: Characterising the Response to Re-challenge in a Controlled Human Infection Model. Open Forum Infectious Diseases, 2017, 4, S227-S228.	0.4	4
121	New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry., 1997, 183, 228.		4
122	Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID) - a phase II study. Cancer Chemotherapy and Pharmacology, 2000, 46, 63-68.	1.1	3
123	Travel medicine has come of age and a new examination marks the 21st birthday. Travel Medicine and Infectious Disease, 2009, 7, 179-180.	1.5	3
124	A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. International Journal of Oncology, 0, , .	1.4	3
125	Molecular analysis reveals somatically mutated and unmutated clonal and oligoclonal B cells in T-cell-rich B-cell lymphoma. Journal of Pathology, 2000, 192, 479-487.	2.1	2
126	Interleukin 2 treatment in HIV-1 infection. Lancet, The, 2006, 367, 1054-1055.	6.3	2

#	Article	IF	CITATIONS
127	Dysuria and a headache. Lancet, The, 2004, 364, 1554.	6.3	1
128	Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA.HIVconsv, in HAART-treated Subjects. AIDS Research and Human Retroviruses, 2014, 30, A190-A190.	0.5	1
129	p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer. Cancer Immunology, Immunotherapy, 1995, 41, 146-150.	2.0	1
130	A flow cytometric study of c-erbB-3 expression in breast cancer. Cancer Immunology, Immunotherapy, 1995, 41, 280-286.	2.0	1
131	CD Rom Review. Tropical Doctor, 2002, 32, 126-126.	0.2	O
132	Reply to Farmakiotis et al. Clinical Infectious Diseases, 2014, 59, 1198-1199.	2.9	0
133	Live attenuated oral vaccine, age and anti-Vi antibody status at baseline significantly affect attack rate in a human Salmonella Typhi challenge model. Journal of Infection, 2015, 71, 689.	1.7	0